Showing 21 - 40 results of 64,632 for search '(( i ae decrease ) OR ( 5 ((((fold decrease) OR (nn decrease))) OR (a decrease)) ))', query time: 0.78s Refine Results
  1. 21
  2. 22
  3. 23
  4. 24
  5. 25
  6. 26
  7. 27

    FTY720 decreased viability, proliferation, and motility and induced apoptosis in human hepatoblastoma cells. by Laura L. Stafman (6577184)

    Published 2019
    “…(B) Following 24 hours of treatment with FTY720, the proliferation of HuH6 cells measured using the CellTiter 96 cell proliferation assay was significantly decreased (IC<sub>50</sub> = 6.4 μM, p ≤ 0.05). (C) HuH6 cells were plated and allowed to reach 80% confluence, at which time the media was changed for fresh media (0, 5, or 8 μM FTY720) and a standard scratch wound was made. …”
  8. 28

    Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5‑ASA–PABA–MAC and 5‑ASA–PABA–Diamine for the T... by Jiaxing Zhao (3965057)

    Published 2022
    “…Specifically, compound <b>20g</b> displayed a 3.67-fold decrease of plasma AUC<sub>(tofacitinib, 0–∞)</sub> and a 9.61-fold increase of colonic AUC<sub>(tofacitinib, 0–12h)</sub>, compared with tofacitinib at a molar equivalent oral dose. …”
  9. 29
  10. 30
  11. 31

    MiR-129-5p levels were decreased in mouse depression models. by Qiaozhen Qin (13159201)

    Published 2025
    “…<p><b>A.</b> Experimental schedule. All mice underwent behavioral tests following CRS treatment. …”
  12. 32
  13. 33
  14. 34
  15. 35
  16. 36

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…</p>Results<p>In a dose-dependent manner, ruxolitinib addition synergizes with UCB-Tregs to suppress SLE-PBMC proliferation, inhibit CD8<sup>+</sup> T cells, and reduce phosphorylation of STAT3/STAT5/AKT in CD8<sup>+</sup> T cells. …”
  17. 37
  18. 38
  19. 39
  20. 40